This review article summarizes the current clinical practice guidelines around disease definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer (NMIBC). Recently completed and ongoing clinical trials of novel and investigational therapies in Bacillus Calmette-Guérin (BCG)-naïve, BCG-recurrent, and BCG-unresponsive patient populations are also described, e.
Open radical cystectomy (ORC) is regarded as the standard treatment for muscle-invasive bladder cancer, but robot-assisted radical cystectomy (RARC) is increasingly used in practice. A recent study showed that RARC resulted in slightly fewer minor but slightly more major complications, although the difference was not statistically significant.
To validate the association of plasma-levels of urokinase-type plasminogen activator (uPA), its soluble receptor (SuPAR) and its inhibitor (PAI-One) with oncologic outcomes in a large cohort of patients treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB).
Prostate-specific membrane antigen (PSMA) is highly expressed by poorly differentiated, metastatic, and castration-resistant prostate cancer cells,1 creating a good imaging and therapeutic target. 177Lutetium (Lu) is a beta-emitting radionuclide that induces DNA strand breaks and cellular lethality.2 In the situation of 177Lu-PSMA-617, 177Lu is linked to a 617, which is a small molecule targeting vector […]
A cornerstone of treatment for advanced prostate cancer is androgen deprivation therapy (ADT). In contrast to this androgen antagonism treatment in prostate cancer, androgen agonism treatment is promising in some types of cancer. The most clinically advanced iteration of this idea is found in estrogen-positive breast cancer. It has been found that the androgen receptor […]
Radiation therapy is a cornerstone of bladder-sparing treatment regimens for patients with muscle-invasive bladder cancer (MIBC). However, a significant number of MIBCs are radioresistant. Components of tumor immune microenvironment (TIME) can mediate tumor radioresistance. Polymorphonuclear neutrophils (PMNs) are known to infiltrate the TIME post-radiation and are associated with adverse outcomes for patients with MIBC. PMNs […]
Introduction In 2021 in the United States, there will be approximately 83,730 new cases of bladder cancer (~64,280 men and 19,450 women) and approximately 17,200 deaths from bladder cancer (12,260 men and 4,940 women). On a global scale, in 2017 it was estimated that there were 2.63 million (95% CI 2.57-2.72 million) bladder cancer cases, […]
Testicular tumors in prepubertal boys account for 1-2% of all solid pediatric tumors. They have a lower incidence, a different histologic distribution and are more often benign compared to testicular tumors in the adolescent and adult group.
To identify the differences in oncological outcomes for patients with different pT3a renal tumor invasion patterns and pathological features. The protocol of this study was registered on PROSPERO (CRD42021234475).
BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment is delayed disease progression. The degree to which early therapeutic success affects downstream outcomes is not well established.
